Services on Demand
On-line version ISSN 1678-9741
Rev Bras Cir Cardiovasc vol.20 no.3 São José do Rio Preto July/Sept. 2005
José Glauco Lobo Filho; Maria Cláudia Leitão; Roberto Augusto Mesquita Lobo; José Mário de Lima Júnior; João Paulo Aguiar Ribeiro; Fernanda Cavalcante; Glício Rebouças; Allison Borges; Dadson Leandro Sales; Newton Teles Júnior
evaluate a methodology of anticoagulation during off-pump coronary artery bypass
surgery (CABS) that promotes safe anticoagulation during the procedure (Activated
Coagulation Time (ACT) > 200 seconds), using an initial dose of 1 mg of
sodium heparin/kg weight.
METHOD: 40 patients (30 men and 10 women), with ages ranging from 41 to 85 years, were submitted to off-pump CABS, using an initial sodium heparin dose of 1mg/kg of weight. Ten minutes after the drug was administered, if the ACT was = 200 seconds, we initiated the revascularization procedure. If not, we administered an additional dose of 0.5mg/kg heparin. During the surgery, the ACT was measured at 30 minute intervals. After revascularization, heparin reversal was achieved with a dose of protamine chloride equal do the total heparin dose infused during the procedure (1:1).
RESULTS: The mean ACT at 10 minutes after heparinization was 372.2 (± 104.31) seconds, without significant statistical difference between gender and age groups (p>0.05). The ACT values at 30 and 60 minutes remained greater than 200 seconds in all patients. The ACT at 30 minutes showed a significant statistical difference between age groups and gender (p<0.05). After heparin reversal using protamine, all patients returned to their initial hemostasis level (ACT < 200s).
CONCLUSION: The results show the safety and effectiveness of an initial sodium heparin dose of 1 mg/kg of weight during off-pump CABS maintaining safe ACTs (> 200s) even after 60 minutes of heparinization, independently of age and gender.
Descriptors: Myocardial Revascularization; Heparin; Whole Blood Coagulation Time
Sodium heparin is the anticoagulant normally used in heart surgery. Pharmacologically, it allows an adequate control of the anticoagulation and the prevention of thromboembolic events, and is responsible for the great development of surgical techniques. However, an adequate and rigorous control of the levels of anticoagulation is necessary, in order to minimize its adverse effects [1,2].
The use of large-dose endovenous sodium heparin in on-pump coronary artery bypass surgery is already well established. Due to the prothrombotic effects induced by the blood circulation in a artificial environment , the anticoagulant doses used are high, with levels of up to 3 to 4 mg (300 to 400 IU) of heparin per kg of body weight , to reach a safe activated coagulation time (ACT) of over than 480 seconds [2,4].
The technical use of off-Pump coronary artery bypass grafting (OPCABG) surgery reduces the incidence of a series of postoperative complications and the time of hospitalization is comparable to the on-pump procedure [5-7], without damaging the anastomoses [7-8]. Thus, we have seen an increase in the use of off-Pump CABG.
In spite of OPCABG becoming a common technique, there is still no consensus about the ideal dose of heparin to be utilized in this new context . Consequently, the heparinization of patients in this type of surgery has been empirically performed by many surgeons. Some even utilize anticoagulation in doses similar to those employed in on-pump CABG, which may be responsible for the high risk of bleeding in the postoperative period thereby increasing the in-hospital time [9-12]. Additionally, proportionally greater doses of protamine must be utilized to revert this heparinization, making the dose-dependent deleterious effects of protamine, such as hypotension, myocardial depression and non-cardiogenic pulmonary edema, possible [12,13].
Remembering that in OPCABG surgery the induction of prothrombotic events is less frequent than in on-pump CABG , patients submitted to this surgical procedure should, thus, receive differentiated trans-operative anticoagulation, at lower doses.
Based on the fact that OPCABG from the physiological, hemodynamical and functional viewpoints, is similar to peripheral vascular surgery, it has been suggested that the use of heparin doses in OPCABG should be similar to those universally accepted in peripheral vascular surgical techniques. As ACT levels over 200 seconds are considered safe in peripheral vascular procedures, according to current publications [12,14,15], our protocol adopted this ACT level as appropriate for patients undergoing anticoagulation in OPCABG.
Consequently, we present a protocol of a safe method of anticoagulation that can be routinely utilized in this type of intervention. We stress that due to individual variations in the necessities of heparin and the risks involved with small doses, monitoring of the anticoagulant activity of heparin during the surgical procedure is essential [16-19].
Forty patients (30 men and 10 women) with ages between 41 and 85 years (mean: 64.02 ± 11.14 years), participated in the study after signing written informed consent forms. The patients were consecutively submitted to elective OPCABG surgery from January to June 2005.
This is an observational-type study, with exclusion criteria of previous coagulopathies, patients submitted to reoperations and those that did not accept to participate in the study. The research was approved by the Ethics Committees of the services where the surgical procedures were performed, according to the protocol as follows:
1. All ACT measurements were performed using the 2000® MCA apparatus (Adib Jatene Foundation). In all measurements 3-mL samples of whole blood collected from a peripheral venous vessel was utilized.
2. Before induction of anesthesia, the ACT of the patient (Initial ACT) was determined.
3. After obtaining the initial ACT, EV sodium heparin in bolus at a dose of l mg/kg of body weight was infused.
4. Another ACT measurement was made 10 minutes after heparin infusion (ACT10). If the determined ACT at this time was 200 seconds or greater, CABG would be initiated. If the ACT was less than 200 seconds, an extra dose of sodium heparin of 0.5 mg/kg of body weight in bolus was administrated EV, aiming at achieving an ACT of more than 200 seconds, defined as safe.
5. At thirty-minute intervals, ACT values were determined (ACT30 and ACT60) and, when they were less than 200 seconds, extra doses of sodium heparin (0.5 mg/kg) were administrated in order to maintain the ACT at over 200 seconds.
6. At the end of CABG, circulating heparin was neutralized by endovenous administration of protamine hydrochloride, controlled using a continuous infusion pump, at a proportion of 1 mg protamine to 1 mg of total heparin administrated. A maximum dose of 50 mg of protamine was administered in each ten minutes.
Ten minutes after the end of protamine infusion, the ACT was measured again (ACTFINAL).
Statistical analysis of the ACT values was made. All the values are in seconds and are reported as arithmetical means, followed by the standard deviation (between parentheses).
To evaluate a possible variation in response between the genders and different age groups to anticoagulation with heparin, we proceeded in the following manner: we obtained mean ACT values of patients from both genders, comparing them and after we utilizing the non-paired t-test. In respect to the analysis of the differences in response according to the age of the patient, we subdivided our sample into three age groups: from 40 to 54 years, from 55 to 69 years and greater than 70 years. For each group the mean value of ACT was obtained and these values were compared among each other utilizing the one-way analysis of variance test (ANOVA). In both tests, a p-value = 0.05 was considered statistically significant (CI=95%).
The mean of the initial ACT values of studied patients was 127.8 (± 30.57) seconds demonstrating its basal level of hemostatic response. Comparing the mean basal ACT values among the male patients (122.4 ± 29.41) and female patients (143.9 ± 29.66), we obtained a borderline value of p (p= 0.0532), but without significant difference. In the analysis of the basal ACT in the different age groups, we obtained mean values of 134.9 (± 37.47) seconds in the group of 40 to 54 year-olds, 132.4 (± 24.09) seconds in group of 55 to 69 years year-olds and 119.3 (± 30.89) seconds in the group of over 70 year-olds. Comparing the mean values, there is no statistically significant difference among age groups (p= 0.3603).
When the ACT10 values were analysed, we observed a mean value of 372.2 (± 104.31) seconds. It was verified that there was no statistically significant variation between the ACT10 of male patients (360.8 ± 106.2) and female patients (406.5 ± 95.13) (p=0.2346) (Figure 1).
To analyze if the ACT10 values presented significant variations among the different age groups, we obtained the following values: from 40 to 54 years (371.1 ± 128.3), from 55 to 69 years (395.9 ± 116.1) and over 70 years (352.2 ± 76.1). Comparing these values, we verified that there were no statistically significant variations among the ACT10 measurements of the different age groups (p= 0.5315) (Figure 2).
In respect to the mean ACT30 value, we calculated it to be 342.27 (± 87.14) seconds. It was thus demonstrated that the heparin dose utilized maintained the patients safely anticoagulated in the thirtieth minute after its administration. Comparing the mean values among male patients (319.2 ± 75.15) and female patients (403.9 ± 90.28), we verified that there was a statistically significant variation, with levels of response to the anticoagulation greater in the female group than those obtained in male group (p-value = 0.0067) (Figure 3).
Comparing the ACT30 among the three aforementioned age groups, we obtained the following values: from 40 to 54 years _ 287.3 (± 67.99), from 55 to 69 years 396.8, (± 87.79) and over 70 years 314.7 (± 73.7). Statistically significant differences were identified with the levels of anticoagulation among the different age groups (p-value = 0.0047) (Figure 4). Using the Newman-Keuls test for multiple comparisons, we observed that this difference occurs only between the 55- to 69-year-old Group and the other two groups. Between the 40- to 54-year-old Group and over 70-year-old Group, there was no statistically significant difference.
For those patients who were still in surgery for coronary anastomoses at 60 minutes after the initial heparinization (13 patients), a new measurement of the ACT was performed. In these patients the mean ACT value was 324.61 (± 98.80) seconds, thus still within safe levels. Again, there was no statistically significant variations between the ACT60 of male patients (321.1 ± 78.3) and female patients (330.3 ± 150.5) (p-value = 0.8979). In respect to an analysis among the different age groups, from 40 to 54 years, from 55 to 69 years and more than 70 years, we obtained the following means, 259.0 (± 78.39), 427.7 (± 123.1) and 316.8 (± 61.6) respectively. There was also no statistically significant difference between these values (p= 0.0645).
In respect to the additional heparinization, only one patient presented with an ACT10 less than the minimum of 200 seconds. An extra dose of 0.5 mg/kg of weight of sodium heparin was administrated to this patient. After this dose, the patient's ACT increased from 168 seconds (ACT10) to 403 seconds.
Completing the surgical time corresponding to coronary anastomoses and the protamine infusion the ACTFINAL was checked. At this moment, the mean time was from 120.47 (± 22.83) seconds, demonstrating adequate neutralization of the circulating heparin and an efficient return to the initial levels of hemostasis for the patients. Comparing male and female patients, the mean values were 116.4 (± 22.65) and 132.7 (± 19.6) seconds respectively, giving a statistically significant difference between genders (p-value = 0.0492) (Figure 5). When comparing the values among the three age groups, the mean ACTs were 123.8 (± 29.71), 124.9 (± 22.5) and 114.6 (± 18.01), respectively. No statistically significant differences between the ACTFINAL values and the different age groups were identified (p-value = 0.417) (Figure 6).
With the growing use of the OPCABG, the number of scientific publications, both national and international, related to the use of this surgical technique has increased considerably. However, there are the several gaps in the scientific literature about the most adequate heparin doses to be employed in this procedure. Through this study, our group aimed at maintaining the levels of anticoagulation of patients submitted to OPCABG to reduced doses of heparin of 1 mg/kg of body weight, similar to the doses utilized in the peripheral vascular surgery.
A concern at the start of the study was about individual variations among patients who could respond heterogeneously to the standard heparin dose, as has already been reported in published studies [16-19]. To try to get around this problem, we adopted the practice of intraoperative monitoring of the ACT, attempting to continuously measure the response of each patient to the heparinization and to immediately increase the dose if patients did not present adequate anticoagulation for the procedure [20,21]. Accordingly, we determined a safety level to perform the surgery with an ACT of at least 200 seconds.
Only one patient presented an unsatisfactory ACT of less than 200 seconds at 10 minutes after heparinization, but the ACT increased immediately to a safe level with an additional dose of 0.5 mg heparin/kg of body weight.
In the other patients, the proposed heparinization gave an effective ACT level, with mean values of 372.2 (± 104.31) seconds after administration, well over the pre-established minimum of 200 seconds, a level at which there is surely no intravascular coagulation . We also demonstrated that, independently of gender or age the ACT10 level was always greater than the acceptable minimum. That is, even taking into account individual variations, differences in gender and age, the utilization of this heparin dose is capable of inducing a safe anticoagulation level, well above the minimum of 200 seconds stipulated by previous studies [12,14,15].
This level of heparinization was even adequate 30 minutes after heparin infusion, as the mean ACT30 was 342.27 (± 87.14) seconds. At this time interval, variables such as gender and age influenced the degree of response to heparinization. However, even responding differently, all patients remained above the safety level.
In those patients in which anastomoses were still being performed 60 minutes after the initiation of heparinization, the ACT was, on average, 324.61 (± 98.80) seconds, still considered an adequate level. At this point we can affirm that patients submitted to OPCABG using doses of 1 mg of sodium heparin per kilogram of body weight are safely maintained anticoagulated during all the period necessary to perform the coronary anastomosis procedure.
At the end of the anastomoses, reversal of the heparin was initiated using protamine hydrochloride at a proportion of 1:1. This total reversal at the end of OPCABG, is known to avoid complications such as excessive postoperative bleeding, and the consequent need of blood derivatives and their inherent risks [8,18]. Ten minutes after the end of the infusion of the protamine, the TCAFINAL had a mean value of 120.47 (± 22.83) seconds. At this moment, there was a slight difference between the genders, again with women having higher ACTs. However, differences among age groups were not identified.
Nevertheless, even with possible individual variations, the heparin reversal protocol brought all patients back to safe hemostasis states practically similar states to those obtained before the start of the surgical procedure, where the mean ACT was 127.8 (± 30.57) seconds (p-values = 0.2284).
The results presented in this study demonstrate the safety and efficacy of anticoagulation of patients who will be submitted to OPCABG utilizing low doses of sodium heparin 1 mg/kg of body weight. In all patients the response was satisfactory with safe ACTs, adequate to complete the procedure. We also demonstrated that this response lasts for at least 30 minutes or even 60 minutes after initiation of heparinization, maintaining the patient safely anticoagulated throughout.
The efficiency of heparin reversal with protamine at a proportion of 1:1 (total reversion), is also evident, returning the hemostasis of the patients at the end of the surgical procedure to levels similar to the basal level (Figure 7).
It was also clear that, independently of variables such as gender and age, heparinization at the proposed dose allows adequate levels of anticoagulation to be achieved. Even when the response was statistically different between the genders or age groups, as seen with the ACT30 and the ACTFINAL, this does not put the patient at risk, because the ACTs remain at adequate levels.
Finally, we believe that according to the results presented in this study, the efficiency of the anticoagulation using 1 mg of sodium heparin/kg of body weight for patients submitted to OPCABG was proven, maintaining the ACTs at safe levels (200 seconds), minimizing the adverse effects resulting from heparinization.
We wish thank to the anesthesiology staff, composed of Dr. Fernando Lima Verde, Dr. Júlio Alexandre and Dr. Geraldo Silva, for the invaluable help they gave in the exact monitoring of the trans-operative ACT levels. We also wish to thank Dr. Ausonius Saraiva, resident physician in our service, who was willing to help us in all surgical procedures and to the secretary Patrícia Queiroz de Sousa, always ready to offer us assistance during all the study period.
1. Doty DB, Knott HW, Hoyt JL, Koepke JA. Heparin dose for accurate anticoagulation in cardiac surgery. J Cardiovasc Surg. 1979;20(6):597-604. [ Links ]
2. Cohen JA. Activated coagulation time method for control of heparin is reliable during cardiopulmonary bypass. Anesthesiology. 1984;60(2):121-4. [ Links ]
3. Englberger L, Immer FF, Eckstein FS, Berdat PA, Haeberli A, Carrel TP. Off-pump coronary artery bypass operation does not increase procoagulant and fibrinolytic activity: preliminary results. Ann Thorac Surg. 2004;77(5):1560-6. [ Links ]
4. Hattersley PG. Activated coagulation time of whole blood. JAMA. 1966;196(5):436-40. [ Links ]
5. Milani R, Brofman P, Varela A, Souza JA, Guimarães M, Pantarolli R et al. Revascularização do miocárdio sem circulação extracorpórea em pacientes acima de 75 anos: análise dos resultados imediatos. Arq Bras Cardiol. 2005;84(1):34-7. [ Links ]
6. Atik FA, Miana LA, Jatene FB, Auler Júnior JOC, Oliveira SA. A cirurgia de revascularização do miocárdio sem circulação extracorpórea minimiza o sangramento pós-operatório e a necessidade transfusional. Arq Bras Cardiol. 2004;83(4):332-7. [ Links ]
7. Lima RC, Escobar MAS, Lobo Filho JG, Diniz R, Saraiva A, Césio A et al. Resultados cirúrgicos na revascularização do miocárdio sem circulação extracorpórea: análise de 3.410 pacientes. Rev Bras Cir Cardiovasc. 2003;18(3):261-7. [ Links ]
8. Cheng DC, Bainbridge D, Martin JE, Novick, RJ. Does off-pump coronary artery bypass reduce mortality, morbidity, and resource utilization when compared with conventional coronary artery bypass? A meta-analysis of randomized trials. Anesthesiology. 2005;102(1):188203. [ Links ]
9. Shuhaibar MN, Hargrove M, Millat MH, O'Donnell A, Aherne T. How much heparin do we really need to go on pump? A rethink of current practices. Eur J Cardiothorac Surg. 2004;26(5):947-50. [ Links ]
10. Garachemani AR, Kaufmann U, Fleisch M, Meier B. Prolonged heparin after uncomplicated coronary interventions: a prospective, randomized trial. Am Heart J. 1998;136(2):352-6. [ Links ]
11. Grubitzsch H, Wollert HG, Eckel L. Emergency coronary artery bypass grafting: does excessive preoperative anticoagulation increase bleeding complications and transfusion requirements? Cardiovasc Surg. 2001;9(5):510-6. [ Links ]
12. Gatti G, Pugliese P. Heparin reversal in off-pump coronary artery bypass surgery: complete, partial, or no reversal? Cardiovasc Surg. 2002;10(3):245-50. [ Links ]
13. Szalados JE, Ouriel K, Shapiro JR. Use of the activated coagulation time and heparin dose-response curve for the determination of protamine dosage in vascular surgery. J Cardiothorac Vasc Anesth. 1994;8(5):515-8. [ Links ]
14. Anacleto A, Anaclet, JC. Hemoterapia, coagulopatia e heparinoterapia em cirurgia vascular. In: Maffei FHA, editor. Doenças vasculares periféricas. Vol. 1. 3a ed. Rio de Janeiro:Editora Medsi;2002. p.605-24. [ Links ]
15. Jacobsen W, Brauer F, Smith LL. Heparin activity monitoring during vascular surgery. Am J Surg. 1978;136(1):141-4. [ Links ]
16. Bull BS, Korpman RA, Huse WM, Briggs BD. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg. 1975;69(5):674-84. [ Links ]
17. Bull BS, Huse WM, Brauer FS, Korpman RA. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg. 1975;69(5):685-9. [ Links ]
18. Martin P, Greenstein D, Gupta NK, Walker DR, Kester RC. Systemic heparinization during peripheral vascular surgery: thromboelastographic, activated coagulation time, and heparin titration monitoring. J Cardiothorac Vasc Anesth. 1994;8(2):150-2. [ Links ]
19. Warner MF, Mian MS, Missri JC. Activated clotting-time variability in patients undergoing coronary angioplasty. Clin Cardiol. 1994;17(7):372-4. [ Links ]
20. Patteril M, Stafford-Smith M, Toffaletti JG, Bute BP, Milano CA, Welsby IJ. Changing systems for measuring activated clotting times: impact on the clinical practice of heparin anticoagulation during cardiac surgery. Clin Chim Acta. 2005;356(1-2):218-24. [ Links ]
21. Leyvi G, Zhuravlev I, Inyang A, Vinluam J, Ramachandran S, Lehning EJ et al. Arterial versus venous sampling for Activated Coagulation Time measurementes during cardiac surgery: a comparative study. J Cardiothorac Vasc Anesth. 2004;18(5):573-80. [ Links ]
22. Nader ND, Khadra WZ, Reich NT, Bacon DR, Salermo TA, Panos AL. Blood product use in cardiac revascularization: comparison of on- and off-pump techniques. Ann Thorac Surg. 1999;68(5):1640-3. [ Links ]
Correspondence to Article received
in May, 2005 Work performed
in the Cardiac Surgery Department of ICORP; Hospital Regional da Unimed; Hospital
Monte Klinikum; Hospital Universitário Walter Cantídio (HUWC)
of the Ceará Federal University (UFC), Fortaleza, CE, Brazil.
ICORP Instituto do Coração e Pulmão
Rua Dr José Lourenço, 625, Aldeota
Fortaleza (CE), Brazil, CEP 60115-280
Telephone: (85) 3244-1711
Fax: (85) 3261-0816
E-mail: firstname.lastname@example.org, email@example.com
Article accepted in August, 2005
in May, 2005
Work performed in the Cardiac Surgery Department of ICORP; Hospital Regional da Unimed; Hospital Monte Klinikum; Hospital Universitário Walter Cantídio (HUWC) of the Ceará Federal University (UFC), Fortaleza, CE, Brazil.